AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2012
Nov 1, 2012
30583_dirs_2012-11-01_dc8eb033-ac18-423b-958d-9b129ea80990.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2012-10-31
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-10-31 | Common Stock | M | 3000 | $9.86 | Acquired | 178691 | Direct |
| 2012-10-31 | Common Stock | S | 3000 | $37.6820 | Disposed | 175691 | Direct |
| 2012-10-31 | Common Stock | S | 1000 | $38.81 | Disposed | 174691 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-10-31 | Stock Option (right to buy) | $9.86 | M | 3000 | Disposed | 2015-11-10 | Common Stock (3000) | Direct |
Footnotes
F1: Transaction made pursuant to a Rule 10b5-1 Trading plan executed on March 12, 2012.
F2: The price in Column 4 is a weighted average price. The prices actually received ranged from $37.14 to $38.73. The reporting person will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Transaction made pursuant to a Rule 10b5-1 plan executed on March 14, 2012.
F4: Original option grant vested 1/3 each May 11, 2006, May 11, 2007, and May 11, 2008.